For example, loss of FOS indicates worse overall survival in patients with breast cancer (45) while increased expression of FOSL1 and JUN family members promotes drug resistance and growth in breast and colorectal cancer cells (46, 47). This evidence concerns the gene FOS and colorectal cancer.